FDA Brief

Company record

BioSpectra, Inc.

0 FDA warning letters since 2023 and 1 recall in the last 12 months.

Get an email the day FDA posts anything new about BioSpectra, Inc..

Recalls

ReportedClassFirmProduct and reason
Oct 14 Class II BioSpectra, Inc.
Drug
Biospectra Tris/Tromethamine, USP, GMP, API Grade, Manufactured at 100 Majestic Way, Bangor, PA 18013, NDC 64173-101-25
Failed stability specifications